BIOCRYST PHARMACEUTICALS INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
BioCryst reported Q3 2026 total net revenue of $180.3M (+13% YoY), with ORLADEYO contributing $174.8M. The company achieved GAAP operating profit of $53.3M and non-GAAP operating profit of $86.5M. FDA approved ORLADEYO 150mg oral pellets for patients 12 and older in October 2026. The company maintained full-year ORLADEYO revenue guidance at $625–645M but raised total revenue guidance to $715–730M (from $690–715M), and improved non-GAAP operating expense guidance to $415–425M (from $420–440M), driven by higher navenibart licensing revenue and continued Birmingham site closure progress ($10M total cost; $30–35M annualized savings).
Why this rating
Strong Q3 execution with 9% YoY ORLADEYO growth and raised FY guidance are meaningful. At ~$1.9B market cap, $180M quarterly revenue and $86.5M non-GAAP operating profit represent solid core business performance. However, no transformational events; pipeline (navenibart results Q3 2027, BCX17725 data year-end) remains forward-looking. Modest guidance raises don't materially alter trajectory.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.